Heavy Periods: Drugs That Cause or Treat Menorrhagia

What Counts as a Heavy Period?

The American College of Obstetricians and Gynecologists (ACOG) defines heavy menstrual bleeding as blood loss exceeding 80 mL per cycle or bleeding that lasts longer than 7 days [1]. In practice, most clinicians ask whether bleeding interferes with daily activities, because measuring volume at home is unreliable.

Clinical Signs That Point to Menorrhagia

Soaking through a pad or tampon in under an hour, passing clots larger than a quarter, or needing to double up on protection are all red flags. Night-time flooding that disrupts sleep is another marker clinicians take seriously.

The PBAC Scoring Method

The Pictorial Blood Assessment Chart (PBAC) assigns point values to each pad, tampon, or clot recorded over one cycle. A score above 100 correlates with blood loss greater than 80 mL and is widely used in clinical trials to standardize the diagnosis [2]. This scoring tool gives patients a concrete way to communicate severity to their provider.

Iron Deficiency: The Silent Consequence

Chronic heavy bleeding is the leading cause of iron-deficiency anemia in premenopausal women. A 2019 analysis published in The Lancet estimated that 33% of reproductive-age women globally are anemic, with menstrual loss as the primary driver in non-malarial regions [3]. Checking serum ferritin (not just hemoglobin) catches early depletion before frank anemia develops.

Drugs That Can Cause or Worsen Heavy Periods

Some widely prescribed medications increase menstrual flow as a side effect. Recognizing this link can prevent unnecessary workups and guide treatment adjustments.

Anticoagulants and Antiplatelet Agents

Warfarin, rivaroxaban, apixaban, and enoxaparin all raise the risk of menorrhagia. A prospective cohort study found that 66% of women on warfarin reported heavy menstrual bleeding, compared with 13% of age-matched controls [4]. Direct oral anticoagulants (DOACs) carry a similar signal. A 2020 systematic review in Thrombosis Research reported that 20 to 44% of premenopausal women on rivaroxaban experienced heavy periods [5]. Dose adjustment alone rarely solves the problem; adding tranexamic acid or a levonorgestrel IUD is often needed.

Copper Intrauterine Devices

The copper IUD (Paragard) increases menstrual blood loss by 20 to 50% in the first 3 to 6 months after insertion [6]. This is a mechanical and inflammatory effect, not hormonal. For women who chose the copper IUD specifically to avoid hormones, switching to a levonorgestrel IUD or adding an NSAID during menses can offset the heavier flow.

SSRIs and SNRIs

Selective serotonin reuptake inhibitors impair platelet aggregation by depleting platelet serotonin stores. Case series and pharmacovigilance data link fluoxetine, sertraline, and venlafaxine to increased menstrual bleeding [7]. The risk rises when SSRIs are combined with NSAIDs or anticoagulants.

Other Medications to Watch

Valproic acid, tamoxifen, and certain herbal supplements (dong quai, ginkgo biloba, high-dose fish oil) have all been associated with heavier periods. Tamoxifen acts as a partial estrogen agonist on the endometrium and can cause both heavy bleeding and endometrial polyps [8].

First-Line Treatments for Heavy Menstrual Bleeding

Treatment depends on whether the patient wants contraception, the suspected cause, and how severe the bleeding is. Guidelines from ACOG and the National Institute for Health and Care Excellence (NICE) both recommend starting with medical therapy before considering surgery [1][9].

Levonorgestrel Intrauterine System (Mirena, Liletta)

The 52 mg levonorgestrel IUD is the single most effective medical treatment for menorrhagia. A landmark trial published in the New England Journal of Medicine compared the levonorgestrel IUD with usual medical treatment (oral progestins, tranexamic acid, or mefenamic acid) in 571 women. At 2 years, quality-of-life scores were significantly higher in the IUD group, and 64% fewer women in the IUD arm ultimately needed hysterectomy [10].

Bleeding reduction reaches 71 to 95% by 3 months and up to 97% by 12 months [11]. About 20% of users become amenorrheic within the first year. The device also provides contraception for up to 8 years (Mirena) or 8 years (Liletta).

Tranexamic Acid

Tranexamic acid is an antifibrinolytic that stabilizes clots within the endometrium. The FDA-approved dose for menorrhagia is 1,300 mg orally three times daily for up to 5 days during menstruation [12]. Randomized trials show a 26 to 54% reduction in measured blood loss compared with placebo [13].

It is non-hormonal and taken only during bleeding days, which makes it attractive for women who cannot or prefer not to use hormones. Tranexamic acid should not be combined with hormonal contraceptives containing estrogen in patients with thrombotic risk factors without careful evaluation, though recent data suggest the absolute clot risk remains low in healthy women [12].

Combined Oral Contraceptives

Any monophasic combined pill containing 30 to 35 mcg ethinyl estradiol reduces menstrual blood loss by 40 to 50% [14]. Extended-cycle regimens (84 active pills followed by 7 placebo, or continuous use) further reduce the number of bleeding episodes per year. ACOG recommends combined oral contraceptives as a first-line option for women who also want contraception [1].

Oral Progestins

Norethindrone acetate (5 mg daily for days 5 through 26) or medroxyprogesterone acetate (10 mg daily for 10 days per cycle) reduces blood loss by 80 to 87% when dosed cyclically in the luteal phase or for extended periods [15]. Oral progestins are especially useful when estrogen is contraindicated (history of migraine with aura, VTE risk, or smokers over 35).

NSAIDs

Mefenamic acid (500 mg three times daily during menses) and naproxen (500 mg twice daily) reduce menstrual blood loss by 20 to 40% through prostaglandin synthesis inhibition [16]. NSAIDs are a reasonable first step when bleeding is mildly elevated, and they also treat dysmenorrhea. They are less effective than the levonorgestrel IUD or tranexamic acid for moderate-to-severe menorrhagia.

Second-Line and Procedural Options

When first-line drugs fail or when structural pathology (fibroids, polyps, adenomyosis) is present, procedural interventions become relevant.

GnRH Agonists and Antagonists

Leuprolide acetate (Lupron) and the newer oral GnRH antagonist elagolix (with add-back therapy) can suppress menstruation almost entirely. The ELARIS UF-1 and UF-2 trials (combined N=790) showed that elagolix 300 mg twice daily with add-back reduced heavy menstrual bleeding to normal levels in 68.5% of women with fibroids, versus 8.7% on placebo at 6 months [17]. Side effects include bone density loss and vasomotor symptoms, which is why add-back estrogen/progestin therapy is standard.

Endometrial Ablation

Ablation destroys the endometrial lining and reduces bleeding in 80 to 90% of patients. It is not appropriate for women who may want future pregnancies. Satisfaction rates exceed 85% at 5 years, but roughly 20% of patients ultimately require repeat ablation or hysterectomy within a decade [18].

Hysterectomy

Definitive treatment. Reserved for cases refractory to medical and less invasive surgical management, or when significant uterine pathology (large fibroids, adenomyosis) makes conservative treatment unlikely to succeed. The NICE guideline recommends hysterectomy only after all other options have been discussed [9].

Diagnosing the Underlying Cause

A systematic workup prevents treating the symptom while missing the disease. The PALM-COEIN classification system, developed by the International Federation of Gynecology and Obstetrics (FIGO), categorizes causes of abnormal uterine bleeding into structural (Polyp, Adenomyosis, Leiomyoma, Malignancy) and non-structural (Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not yet classified) groups [19].

Laboratory Testing

The minimum panel includes a complete blood count, serum ferritin, TSH, and a pregnancy test. Women under 20 or those with a lifelong history of heavy bleeding should be screened for von Willebrand disease and platelet function disorders. Von Willebrand disease is present in up to 13% of women presenting with menorrhagia, according to a systematic review in Obstetrics & Gynecology [20].

Imaging

Transvaginal ultrasound is the first-line imaging modality. Saline-infusion sonohysterography improves sensitivity for intracavitary lesions like polyps and submucosal fibroids. MRI is reserved for complex cases (adenomyosis characterization or surgical planning for large fibroids).

Endometrial Biopsy

Indicated for all women over 45 with abnormal bleeding, and for women under 45 with risk factors for endometrial hyperplasia (obesity, chronic anovulation, tamoxifen use, or failed medical therapy) [1].

Special Populations

Adolescents

Heavy periods in the first 2 to 3 years after menarche are common due to anovulatory cycles. Still, coagulopathies are overrepresented in this group. The ACOG Committee Opinion recommends screening for bleeding disorders in any adolescent presenting with menorrhagia at menarche, particularly if bleeding required hospitalization or transfusion [21].

Perimenopause

Erratic cycles and heavier flow are expected during the menopause transition, but endometrial pathology must be excluded. The levonorgestrel IUD serves double duty here: it treats heavy bleeding and provides endometrial protection for women using estrogen therapy for vasomotor symptoms.

Women on Anticoagulation

This group presents a management challenge. Stopping or reducing anticoagulation is often not safe. A 2021 consensus statement from the International Society on Thrombosis and Haemostasis recommended the levonorgestrel IUD as the preferred treatment for anticoagulation-associated menorrhagia, with tranexamic acid as the non-hormonal alternative [22]. Tranexamic acid at standard menstrual doses does not appear to increase systemic thrombotic risk in women on therapeutic anticoagulation, based on available observational data.

When to Seek Medical Attention

Any of the following should prompt an urgent visit: soaking through one or more pads or tampons every hour for more than 2 consecutive hours, passing clots larger than a golf ball, bleeding accompanied by dizziness or shortness of breath, or hemoglobin below 8 g/dL. Chronic heavy periods that cause fatigue and low ferritin (below 30 ng/mL) also warrant treatment rather than reassurance.

Dr. Malcolm Munro, professor of obstetrics and gynecology at UCLA and co-author of the FIGO PALM-COEIN system, has stated: "Heavy menstrual bleeding is not a diagnosis. It is a symptom that requires systematic evaluation before any treatment is prescribed" [19].

The Endocrine Society's 2022 clinical practice guideline on premenopausal abnormal uterine bleeding reinforces this point: "Empiric hormonal therapy should not replace a structured diagnostic evaluation in women with new-onset heavy menstrual bleeding" [23].

Serum ferritin below 30 ng/mL in a menstruating woman with heavy periods warrants oral iron replacement (ferrous sulfate 325 mg every other day, which maximizes absorption based on hepcidin kinetics) alongside definitive treatment of the bleeding itself [24].